{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:49:56Z","timestamp":1772120996266,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jash.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T16:24:25Z","timestamp":1500740665000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-5863","authenticated-orcid":false,"given":"Pauline W.M.","family":"Voskamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedo W.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merel","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-2013","authenticated-orcid":false,"given":"Ellen K.","family":"Hoogeveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2017.07.006_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2017.07.006_bib2","series-title":"Kidney disease and renal function. Health Center Survey for England","author":"Roth","year":"2010"},{"key":"10.1016\/j.jash.2017.07.006_bib3","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2017.07.006_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2017.07.006_bib5","first-page":"405","article-title":"KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"77","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2017.07.006_bib6","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study","volume":"18","author":"Perkovic","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2017.07.006_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2017.07.006_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2017.07.006_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2017.07.006_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2017.07.006_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jash.2017.07.006_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jash.2017.07.006_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2017.07.006_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?","volume":"10","author":"van den Meiracker","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2017.07.006_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials","volume":"67","author":"Xie","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jash.2017.07.006_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/ki.2010.225","article-title":"Have we fallen off target with concerns surrounding dual RAAS blockade?","volume":"78","author":"Lattanzio","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2017.07.006_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2369-15-91","article-title":"Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients","volume":"15","author":"Nacak","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jash.2017.07.006_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ndt\/gfm022","article-title":"EBPG guideline on dialysis strategies","volume":"22","author":"Tattersall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jash.2017.07.006_bib19","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jash.2017.07.006_bib20","first-page":"7","article-title":"Section I. Measurement of renal function, when to refer and when to start dialysis","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jash.2017.07.006_bib21","series-title":"Multidisciplinary guidelines pre-dialysis","year":"2011"},{"key":"10.1016\/j.jash.2017.07.006_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2017.07.006_bib23","series-title":"(ERA\/EDTA) Registry Annual Report 2009","year":"2011"},{"key":"10.1016\/j.jash.2017.07.006_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jash.2017.07.006_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2017.07.006_bib26","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2017.07.006_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2017.07.006_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jash.2017.07.006_bib29","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2017.07.006_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ndt\/gfs469","article-title":"Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study","volume":"28","author":"Chen","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jash.2017.07.006_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/eb-2012-100851","article-title":"The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment?","volume":"18","author":"Fuchs","year":"2013","journal-title":"Evid Based Med"},{"key":"10.1016\/j.jash.2017.07.006_bib32","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2017.07.006_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ki.1994.58","article-title":"Proteinuria\u2013a direct cause of renal morbidity?","volume":"45","author":"Williams","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2017.07.006_bib34","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2017.07.006_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","article-title":"Assessment and control for confounding by indication in observational studies","volume":"47","author":"Psaty","year":"1999","journal-title":"J Am Geriatr Soc"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171117302619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171117302619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T06:19:07Z","timestamp":1659248347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171117302619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1933171117302619"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2017.07.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.728639007.793540967","asserted-by":"object"}]},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society of Hypertension. All rights reserved.","name":"copyright","label":"Copyright"}]}}